Spotlight on Oncology
The Evolving Treatment Landscape for Higher-Risk Myelodysplastic Syndrome
StartActivity Details
1.0 Contact Hour(s)
Expires: June 2, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, hematologists/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with MDS.
Learning Objectives
After completing this program, participants should be able to:
- Describe approaches for MDS diagnosis, classification, and risk stratification using hematologic, morphologic, clinical, and cytogenetic assessments
- Outline available treatment approaches and associated outcomes for patients with MDS based on risk stratification, patient factors, clinical evidence, and available guidelines
- Evaluate the clinical data regarding the efficacy and safety of emerging therapies for the treatment of patients with higher-risk MDS
- Review factors that may impact consideration of clinical trial participation in patients with higher-risk MDS
Activity Description
Numerous new targeted therapies have emerged in recent years with early indications of benefit in patients with higher-risk MDS, particularly in combination with HMAs. These emerging options, which employ novel mechanisms of action and distinct molecular targets, may represent the first targeted therapies to improve outcomes in patients with higher-risk MDS. However, given the recent rapid emergence of data, clinicians are challenged to remain up to date on the latest evidence and the potential role of these therapies in the treatment landscape for patients with high-risk MDS. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application. Clinicians will hear up-to-date information on the latest evidence and the potential role of these therapies in the treatment landscape for patients with MDS.
Statement of Educational Need
With the recent advances in targeted therapies for higher-risk MDS, the use of investigational agents is anticipated to expand over the coming years. The introduction of these new agents and combinations into the clinic will likely change the therapeutic landscape for MDS and given the highly variable nature of the disease, will likely create uncertainty over differences in patients who may benefit, efficacy of emerging agents, optimal sequencing and combinations, and safety of the new agents and combinations. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with MDS, current evidence-based recommendations for the management of the disease, and the clinical utility of agents that could significantly impact patient outcomes.
Faculty
Professor of Medicine and Pathology
Director of MDS/MPN/Aplastic Anemia Program
Rush University Medical Center
Chicago, IL
Dr. Shammo has provided the following disclosure information:
- Research Grant: AbbVie, Alexion, AstraZeneca, CTI, Incyte, Kartos, Stemline, BMS
- Stockholder: AbbVie, Takeda, Baxter
- Member, Speakers Bureau: Sanofi, Incyte, Alexion, BMS
- Other: DSMB for NS Pharma and Apellis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by an educational grant from AbbVie, Gilead Sciences, Inc. and Novartis Pharmaceuticals Corp.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: June 2, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, hematologists/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with MDS.
Learning Objectives
After completing this program, participants should be able to:
- Describe approaches for MDS diagnosis, classification, and risk stratification using hematologic, morphologic, clinical, and cytogenetic assessments
- Outline available treatment approaches and associated outcomes for patients with MDS based on risk stratification, patient factors, clinical evidence, and available guidelines
- Evaluate the clinical data regarding the efficacy and safety of emerging therapies for the treatment of patients with higher-risk MDS
- Review factors that may impact consideration of clinical trial participation in patients with higher-risk MDS
Activity Description
Numerous new targeted therapies have emerged in recent years with early indications of benefit in patients with higher-risk MDS, particularly in combination with HMAs. These emerging options, which employ novel mechanisms of action and distinct molecular targets, may represent the first targeted therapies to improve outcomes in patients with higher-risk MDS. However, given the recent rapid emergence of data, clinicians are challenged to remain up to date on the latest evidence and the potential role of these therapies in the treatment landscape for patients with high-risk MDS. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application. Clinicians will hear up-to-date information on the latest evidence and the potential role of these therapies in the treatment landscape for patients with MDS.
Statement of Educational Need
With the recent advances in targeted therapies for higher-risk MDS, the use of investigational agents is anticipated to expand over the coming years. The introduction of these new agents and combinations into the clinic will likely change the therapeutic landscape for MDS and given the highly variable nature of the disease, will likely create uncertainty over differences in patients who may benefit, efficacy of emerging agents, optimal sequencing and combinations, and safety of the new agents and combinations. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with MDS, current evidence-based recommendations for the management of the disease, and the clinical utility of agents that could significantly impact patient outcomes.
Faculty
Professor of Medicine and Pathology
Director of MDS/MPN/Aplastic Anemia Program
Rush University Medical Center
Chicago, IL
Dr. Shammo has provided the following disclosure information:
- Research Grant: AbbVie, Alexion, AstraZeneca, CTI, Incyte, Kartos, Stemline, BMS
- Stockholder: AbbVie, Takeda, Baxter
- Member, Speakers Bureau: Sanofi, Incyte, Alexion, BMS
- Other: DSMB for NS Pharma and Apellis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by an educational grant from AbbVie, Gilead Sciences, Inc. and Novartis Pharmaceuticals Corp.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Oncology Presentations
Taking Stock of the Evolving Treatment Landscape for Acute GvHD in HSCT: Proceedings from a Clinical Olympics℠
StartActivity Details
1.0 ANCC Contact Hour(s)
1.0 ACPE Contact Hour(s)
Expires: January 31, 2024
Provided By
RMEI Medical Education, LLC
Target Audience
Hematology, hematology/oncology, and transplantation clinicians
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Apply available therapies and guidelines for acute graft-versus-host disease (aGVHD) management in hematopoietic stem cell transplantation (HSCT) patients
- Examine current data and ongoing clinical trials of emerging therapies for the management of acute GVHD in the allogeneic HSCT population
Activity Description
Allogeneic hematopoietic cell transplantation is a potentially curative therapy for many malignant and nonmalignant hematologic diseases. Acute graft-versus-host disease (aGVHD) is a common complication associated with this procedure that can affect up to 50% of patients. Patients with aGVHD commonly present with a maculopapular rash, nausea, vomiting, profuse watery diarrhea and abdominal cramping, and hyperbilirubinemia with jaundice. In this educational activity, renowned GVHD experts discuss staging/grading of GVHD, current prophylactic and treatment strategies, and emerging agents.
Chair
Chief, Adult Bone Marrow Transplantation Service
Memorial Sloan Kettering Cancer Center
Associate Professor, Medicine
Weill Cornell Medical College
New York, NY
Faculty
Donald D. and Elizabeth G. Cooke Professor
Chief, Division of Hematologic Malignancies and Cellular Therapy/BMT
Director, Global Cancer
Duke University
Durham, NC
Professor, Pediatrics
Hematology/Oncology
Edith S Briskin and Shirley K Schlafer Research Professor
Blood and Marrow Transplantation Program
University of Michigan
Ann Arbor, MI
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Nelson J. Chao, MD, MBA, has no relevant financial relationship(s) with ineligible companies to disclose.
Sung Won Choi, MD, MS,
has no relevant financial relationship(s) with ineligible companies to
disclose.
Miguel-Angel Perales, MD,
has relevant financial relationships with AbbVie, AlloVir, Astellas, Bristol
Myers Squibb, Celgene, Cidara Therapeutics, Inc., Equillium, ExeVir, Incyte,
Karyopharm Therapeutics Inc, Kite/Gilead, Medigene, Merck, Miltenyi Biotec,
MorphoSys, Nektar Therapeutics, NexImmune, Novartis, Omeros, Orca Bio, Sellas
Life Sciences, Servier, Takeda, VectivBio AG, Vor Biopharma
(Advisor).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME),
the Accreditation Council for Pharmacy Education (ACPE), and the
American Nurses Credentialing Center (ANCC), to provide continuing education
for the healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation
in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1.0 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number - JA4008290-0000-23-001-H01-P)
Type of Activity: Knowledge
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the challenge questions to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM AND
YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent educational grant from CSL Behring LLC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
1.0 ANCC Contact Hour(s)
1.0 ACPE Contact Hour(s)
Expires: January 31, 2024
Provided By
RMEI Medical Education, LLC
Target Audience
Hematology, hematology/oncology, and transplantation clinicians
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Apply available therapies and guidelines for acute graft-versus-host disease (aGVHD) management in hematopoietic stem cell transplantation (HSCT) patients
- Examine current data and ongoing clinical trials of emerging therapies for the management of acute GVHD in the allogeneic HSCT population
Activity Description
Allogeneic hematopoietic cell transplantation is a potentially curative therapy for many malignant and nonmalignant hematologic diseases. Acute graft-versus-host disease (aGVHD) is a common complication associated with this procedure that can affect up to 50% of patients. Patients with aGVHD commonly present with a maculopapular rash, nausea, vomiting, profuse watery diarrhea and abdominal cramping, and hyperbilirubinemia with jaundice. In this educational activity, renowned GVHD experts discuss staging/grading of GVHD, current prophylactic and treatment strategies, and emerging agents.
Chair
Chief, Adult Bone Marrow Transplantation Service
Memorial Sloan Kettering Cancer Center
Associate Professor, Medicine
Weill Cornell Medical College
New York, NY
Faculty
Donald D. and Elizabeth G. Cooke Professor
Chief, Division of Hematologic Malignancies and Cellular Therapy/BMT
Director, Global Cancer
Duke University
Durham, NC
Professor, Pediatrics
Hematology/Oncology
Edith S Briskin and Shirley K Schlafer Research Professor
Blood and Marrow Transplantation Program
University of Michigan
Ann Arbor, MI
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Nelson J. Chao, MD, MBA, has no relevant financial relationship(s) with ineligible companies to disclose.
Sung Won Choi, MD, MS,
has no relevant financial relationship(s) with ineligible companies to
disclose.
Miguel-Angel Perales, MD,
has relevant financial relationships with AbbVie, AlloVir, Astellas, Bristol
Myers Squibb, Celgene, Cidara Therapeutics, Inc., Equillium, ExeVir, Incyte,
Karyopharm Therapeutics Inc, Kite/Gilead, Medigene, Merck, Miltenyi Biotec,
MorphoSys, Nektar Therapeutics, NexImmune, Novartis, Omeros, Orca Bio, Sellas
Life Sciences, Servier, Takeda, VectivBio AG, Vor Biopharma
(Advisor).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME),
the Accreditation Council for Pharmacy Education (ACPE), and the
American Nurses Credentialing Center (ANCC), to provide continuing education
for the healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation
in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1.0 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number - JA4008290-0000-23-001-H01-P)
Type of Activity: Knowledge
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the challenge questions to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM AND
YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent educational grant from CSL Behring LLC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/Refractory Disease? Proceedings from a Clinical Olympics℠
StartActivity Details
1.0 ANCC Contact Hour(s)
Expires: January 29, 2024
Provided By
RMEI Medical Education, LLC
Target Audience
Medical oncologists, hematologists, hematologist-oncologists, pathologists, and oncology nurses
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select an appropriate B cell maturation antigen (BCMA) targeted therapy among approved options for patients with relapsed/refractory (R/R) multiple myeloma (MM)
- Integrate novel BCMA-targeted therapies into the treatment paradigm of R/R MM, with an emphasis on bispecific antibodies
- Manage adverse events (AEs) associated with BCMA-directed therapies in patients with R/R MM
Activity Description
The advent of BCMA-directed therapy fills a significant gap in the treatment of relapsed/refractory multiple myeloma. As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Sundar Jagannath, Dr. María-Victoria Mateos, and Dr. James Hoffman provide privileged insights into optimal selection and integration of BCMA-directed therapies, particularly bispecific antibodies, to maximize patient outcomes.
Chair
Chair, Multiple Myeloma
Professor, Medicine
Icahn School of Medicine at Mount Sinai
Director, Multiple Myeloma Center of Excellence
Tisch Cancer Center Institute
Editor-in-Chief, Clinical Lymphoma, Myeloma & Leukemia
Mount Sinai Hospital
New York, NY
Faculty
Associate Professor, Clinical Medicine
Division of Myeloma (Hematology)
Sylvester Comprehensive Cancer Center (SCCC)
University of Miami
Miami, FL
Associate Professor, Hematology
Director, Myeloma Program
University Hospital of Salamanca
Salamanca, Spain
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
James Hoffman, MD, has relevant financial relationships with Bristol Myers Squibb (Speaker/Speaker’s Bureau).
Sundar Jagannath, MD, FASCO, has relevant financial relationships with Epizyme, Karyopharm Therapeutics (Advisor); Bristol Myers Squibb, Genentech, Janssen Pharmaceuticals, Legend Biotech, Sanofi (Consultant).
María-Victoria Mateos, MD, PhD, has relevant financial relationships with Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Oncopeptides, Inc., Pfizer, Sanofi, Seagen, Inc. (Advisor); Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Pfizer, Sanofi, Takeda (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant
financial relationship(s) with ineligible companies to disclose with the
exception of Sara Fagerlie, PhD, CHCP, medical writer, who had a relevant
financial relationship with Adaptive Biotechnologies (Consultant).
This relevant financial relationship has been divested.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1.0 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at Accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM AND
YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
1.0 ANCC Contact Hour(s)
Expires: January 29, 2024
Provided By
RMEI Medical Education, LLC
Target Audience
Medical oncologists, hematologists, hematologist-oncologists, pathologists, and oncology nurses
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select an appropriate B cell maturation antigen (BCMA) targeted therapy among approved options for patients with relapsed/refractory (R/R) multiple myeloma (MM)
- Integrate novel BCMA-targeted therapies into the treatment paradigm of R/R MM, with an emphasis on bispecific antibodies
- Manage adverse events (AEs) associated with BCMA-directed therapies in patients with R/R MM
Activity Description
The advent of BCMA-directed therapy fills a significant gap in the treatment of relapsed/refractory multiple myeloma. As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Sundar Jagannath, Dr. María-Victoria Mateos, and Dr. James Hoffman provide privileged insights into optimal selection and integration of BCMA-directed therapies, particularly bispecific antibodies, to maximize patient outcomes.
Chair
Chair, Multiple Myeloma
Professor, Medicine
Icahn School of Medicine at Mount Sinai
Director, Multiple Myeloma Center of Excellence
Tisch Cancer Center Institute
Editor-in-Chief, Clinical Lymphoma, Myeloma & Leukemia
Mount Sinai Hospital
New York, NY
Faculty
Associate Professor, Clinical Medicine
Division of Myeloma (Hematology)
Sylvester Comprehensive Cancer Center (SCCC)
University of Miami
Miami, FL
Associate Professor, Hematology
Director, Myeloma Program
University Hospital of Salamanca
Salamanca, Spain
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
James Hoffman, MD, has relevant financial relationships with Bristol Myers Squibb (Speaker/Speaker’s Bureau).
Sundar Jagannath, MD, FASCO, has relevant financial relationships with Epizyme, Karyopharm Therapeutics (Advisor); Bristol Myers Squibb, Genentech, Janssen Pharmaceuticals, Legend Biotech, Sanofi (Consultant).
María-Victoria Mateos, MD, PhD, has relevant financial relationships with Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Oncopeptides, Inc., Pfizer, Sanofi, Seagen, Inc. (Advisor); Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Pfizer, Sanofi, Takeda (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant
financial relationship(s) with ineligible companies to disclose with the
exception of Sara Fagerlie, PhD, CHCP, medical writer, who had a relevant
financial relationship with Adaptive Biotechnologies (Consultant).
This relevant financial relationship has been divested.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1.0 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at Accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM AND
YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Harnessing the Full Potential of Frontline Immunotherapy in Advanced NSCLC: Proceedings from a Clinical Olympics℠
StartActivity Details
1.0 ANCC Contact Hour(s)
Expires: September 28, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Medical oncology and pulmonology clinicians managing patients with advanced NSCLC.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Utilize molecular testing in patients with advanced non-small cell lung cancer (NSCLC) as a guide for frontline treatment selection
- Select optimal frontline immune checkpoint inhibitor regimens in appropriate patients with advanced NSCLC
- Manage potential immune-related adverse events in patients with advanced NSCLC receiving first-line immunotherapy
Activity Description
The advent of frontline immunotherapy has significantly extended survival for certain patients with metastatic non-small cell lung cancer (NSCLC). As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Jared Weiss, Prof. Aleš Ryška, and Dr. Mihaela Aldea provide privileged insights into the nuances of biomarker testing, optimal regimen selection, and management of immune-related adverse events.
Faculty
Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, United States
Head, Fingerland Department of Pathology
Charles University Medical Faculty
Hradec Králové University Hospital
Prague, Czech Republic
Associate Professor, Medical Oncology
Paris-Saclay University
Gustave Roussy
Villejuif, France
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Jared M. Weiss, MD, has relevant financial relationships with AstraZeneca, Boehringer Ingelheim, Eli Lilly, G1 Therapeutics, Merck, Mirati, Sumitomo Dainippon Pharma (Researcher); AbbVie, AstraZeneca, Azira, Eli Lilly, EMD Serono, G1 Therapeutics, Genentech, Genmab, Jazz Pharmaceuticals, Jounce Therapeutics, Nanobiotix, Pfizer, Regeneron, Sumitomo Dainippon Pharma (Consultant); Achilles, En Fuego Therapeutics, Lyell, Nuvalent, Vesselon (Stock/Stockholder).
Prof. MUDr. Aleš Ryška, MD, PhD, has relevant financial relationships with Amgen, Elphogene, Lilly, MSD, Roche (Advisor); Amgen, Bristol-Myers Squibb, Gilead, MSD, Roche (Speaker/Speaker’s Bureau); Roche, Sanofi (Other: Travel Support).
Mihaela Aldea, MD, PhD, has a relevant financial relationship with Sandoz (Other: Travel/Expenses).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1.0 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM AND
YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer Statement
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
1.0 ANCC Contact Hour(s)
Expires: September 28, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Medical oncology and pulmonology clinicians managing patients with advanced NSCLC.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Utilize molecular testing in patients with advanced non-small cell lung cancer (NSCLC) as a guide for frontline treatment selection
- Select optimal frontline immune checkpoint inhibitor regimens in appropriate patients with advanced NSCLC
- Manage potential immune-related adverse events in patients with advanced NSCLC receiving first-line immunotherapy
Activity Description
The advent of frontline immunotherapy has significantly extended survival for certain patients with metastatic non-small cell lung cancer (NSCLC). As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Jared Weiss, Prof. Aleš Ryška, and Dr. Mihaela Aldea provide privileged insights into the nuances of biomarker testing, optimal regimen selection, and management of immune-related adverse events.
Faculty
Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, United States
Head, Fingerland Department of Pathology
Charles University Medical Faculty
Hradec Králové University Hospital
Prague, Czech Republic
Associate Professor, Medical Oncology
Paris-Saclay University
Gustave Roussy
Villejuif, France
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Jared M. Weiss, MD, has relevant financial relationships with AstraZeneca, Boehringer Ingelheim, Eli Lilly, G1 Therapeutics, Merck, Mirati, Sumitomo Dainippon Pharma (Researcher); AbbVie, AstraZeneca, Azira, Eli Lilly, EMD Serono, G1 Therapeutics, Genentech, Genmab, Jazz Pharmaceuticals, Jounce Therapeutics, Nanobiotix, Pfizer, Regeneron, Sumitomo Dainippon Pharma (Consultant); Achilles, En Fuego Therapeutics, Lyell, Nuvalent, Vesselon (Stock/Stockholder).
Prof. MUDr. Aleš Ryška, MD, PhD, has relevant financial relationships with Amgen, Elphogene, Lilly, MSD, Roche (Advisor); Amgen, Bristol-Myers Squibb, Gilead, MSD, Roche (Speaker/Speaker’s Bureau); Roche, Sanofi (Other: Travel Support).
Mihaela Aldea, MD, PhD, has a relevant financial relationship with Sandoz (Other: Travel/Expenses).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1.0 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM AND
YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer Statement
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Current and Emerging Therapies for Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
StartActivity Details
Expires: September 22, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Transplantation, hematology, and hematology/oncology clinicians engaged in the care of patients with GVHD.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Utilize available therapeutic strategies for the prevention and treatment of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT)
- Implement current and emerging strategies to address unmet needs in the management of steroid-refractory acute GVHD in allogeneic HSCT
Activity Description
Allogeneic HSCT is a revolutionary therapeutic discovery, yet despite advances, the procedure still carries substantial risk for complications and death. Even with prophylactic measures, many patients will go on to develop acute graft-versus-host disease (aGVHD). While there are several agents available for the prevention and treatment of aGVHD, there are still many unmet needs. In this Clinical Reflections® activity, learners will be presented with 2 cases of aGVHD and challenged by expert faculty to reflect back on how they could have been better managed. Faculty will then discuss current guidelines; prevention and treatment options; and emerging agents for prevention, first-line therapy, and steroid-refractory aGVHD.
Faculty
Associate Professor, Medicine
Hematology/Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Assistant Professor, Pediatrics
Harvard Medical School
Medical Director, Clinical Research and Clinical Development
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Christine N. Duncan, MD, has relevant financial relationships with bluebird bio, Inc., Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Omeros, Tome Biosciences (Consultant).
Doris M. Ponce, MD, has relevant financial relationships with Incyte Corporation, Kadmon Corporation (Advisor); CareDx, Ceramedix, Evive Biotech, Kadmon Corporation (Consultant); Incyte Corporation (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support of improving
patient care, RMEI Medical Education, LLC is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from CSL Behring LLC.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Activity Details
Expires: September 22, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Transplantation, hematology, and hematology/oncology clinicians engaged in the care of patients with GVHD.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Utilize available therapeutic strategies for the prevention and treatment of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT)
- Implement current and emerging strategies to address unmet needs in the management of steroid-refractory acute GVHD in allogeneic HSCT
Activity Description
Allogeneic HSCT is a revolutionary therapeutic discovery, yet despite advances, the procedure still carries substantial risk for complications and death. Even with prophylactic measures, many patients will go on to develop acute graft-versus-host disease (aGVHD). While there are several agents available for the prevention and treatment of aGVHD, there are still many unmet needs. In this Clinical Reflections® activity, learners will be presented with 2 cases of aGVHD and challenged by expert faculty to reflect back on how they could have been better managed. Faculty will then discuss current guidelines; prevention and treatment options; and emerging agents for prevention, first-line therapy, and steroid-refractory aGVHD.
Faculty
Associate Professor, Medicine
Hematology/Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Assistant Professor, Pediatrics
Harvard Medical School
Medical Director, Clinical Research and Clinical Development
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Christine N. Duncan, MD, has relevant financial relationships with bluebird bio, Inc., Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Omeros, Tome Biosciences (Consultant).
Doris M. Ponce, MD, has relevant financial relationships with Incyte Corporation, Kadmon Corporation (Advisor); CareDx, Ceramedix, Evive Biotech, Kadmon Corporation (Consultant); Incyte Corporation (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support of improving
patient care, RMEI Medical Education, LLC is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from CSL Behring LLC.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Advances in Cervical Cancer: Addressing Unmet Needs in an Evolving Therapeutic Landscape
StartActivity Details
1.0 Contact Hour(s)
Expires: July 13, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, gynecologic oncologists, oncology nurses, NPs/PAs, pharmacists and other healthcare professionals involved in the treatment of patients with cervical cancer.
Learning Objectives
After completing this program, participants should be able to:
- Assess clinical trial data of newly approved and emerging investigational agents for the treatment of recurrent or metastatic cervical cancer, and their potential role in the context of existing treatment paradigms
- Integrate novel therapies into treatment plans for patients with recurrent or metastatic cervical cancer based on available guidelines, clinical trial data, and sequencing considerations
- Identify and manage adverse events (AEs) associated with novel agents to promote adherence to therapy and optimize patient care
- Incorporate multidisciplinary strategies into current clinical practice to provide best possible care of patients with recurrent or metastatic cervical cancer
Activity Description
This education activity is designed to provide the health-care team with the latest developments and critical insights into the treatment of recurrent or metastatic cervical cancer. This education will support the health-care professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
To provide optimal care to patients with recurrent or metastatic cervical cancer, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact patient outcomes. New and emerging therapies have significantly modified the treatment landscape in recurrent or metastatic cervical cancer. Due to the overwhelming amount of data that have been released in recent years, clinicians require education on the most relevant information, as well as identifying and managing treatment-related AEs, that will enable them to significantly enhance patient outcomes.
Faculty
Gynecology/Oncology
US Oncology Research
Texas Oncology
Texas, United States
Disclosure
- Scientific Steering Committee: AbbVie, AstraZeneca, Clovis Oncology, Genmab/Seagen, Immunogen, Janssen, Merck, Pfizer, Roche/Genentech, GSK, Deciphera, Zentalis, Alkermes, Agenus, Karyopharm, Mersana, Gradalis, Epsilogen
- Research Funding: AstraZeneca, Abbvie, Clovis Oncology, Genmab/Seagen, Merck, Novartis, Roche/Genentech, Zentalis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this Enduring Activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/
Physician Assistants/ Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University designates this Enduring Activity for a maximum of one (1.0)
nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by an educational grant from Seagen and Genmab.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: July 13, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, gynecologic oncologists, oncology nurses, NPs/PAs, pharmacists and other healthcare professionals involved in the treatment of patients with cervical cancer.
Learning Objectives
After completing this program, participants should be able to:
- Assess clinical trial data of newly approved and emerging investigational agents for the treatment of recurrent or metastatic cervical cancer, and their potential role in the context of existing treatment paradigms
- Integrate novel therapies into treatment plans for patients with recurrent or metastatic cervical cancer based on available guidelines, clinical trial data, and sequencing considerations
- Identify and manage adverse events (AEs) associated with novel agents to promote adherence to therapy and optimize patient care
- Incorporate multidisciplinary strategies into current clinical practice to provide best possible care of patients with recurrent or metastatic cervical cancer
Activity Description
This education activity is designed to provide the health-care team with the latest developments and critical insights into the treatment of recurrent or metastatic cervical cancer. This education will support the health-care professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
To provide optimal care to patients with recurrent or metastatic cervical cancer, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact patient outcomes. New and emerging therapies have significantly modified the treatment landscape in recurrent or metastatic cervical cancer. Due to the overwhelming amount of data that have been released in recent years, clinicians require education on the most relevant information, as well as identifying and managing treatment-related AEs, that will enable them to significantly enhance patient outcomes.
Faculty
Gynecology/Oncology
US Oncology Research
Texas Oncology
Texas, United States
Disclosure
- Scientific Steering Committee: AbbVie, AstraZeneca, Clovis Oncology, Genmab/Seagen, Immunogen, Janssen, Merck, Pfizer, Roche/Genentech, GSK, Deciphera, Zentalis, Alkermes, Agenus, Karyopharm, Mersana, Gradalis, Epsilogen
- Research Funding: AstraZeneca, Abbvie, Clovis Oncology, Genmab/Seagen, Merck, Novartis, Roche/Genentech, Zentalis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this Enduring Activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/
Physician Assistants/ Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University designates this Enduring Activity for a maximum of one (1.0)
nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by an educational grant from Seagen and Genmab.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Contemporary Treatment of Endometrial Cancer: An In The Clinic Activity
StartActivity Details
Expires: June 30, 2023
Provided By
Integrity Continuing Education, Inc.
Statement of Commercial Support
This educational activity is supported by educational grants from Eisai Inc., GlaxoSmithKline, and Merck Sharp & Dohme Corp.
Target Audience
This educational activity has been designed to meet the needs of medical and gynecologic oncologists, physician assistants, and nurse practitioners who treat and manage patients with gynecologic malignancies, with a focus on the community-based clinician.
Activity Description
The treatment options for advanced or recurrent endometrial cancer (EC)
have changed dramatically in the last five years. Molecular testing to
identify patients that could benefit from targeted treatments is now
recommended for all patients. Choosing the optimal treatment can be complex
as treatment planning must consider molecular signatures, safety and efficacy
data, patient and tumor characteristics, and guideline recommendations.
In this edition of In the Clinic, Drs. Murphy and Westin will unpack
the latest clinical trial data and review best practices for approaching
treatment for these patients.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Elucidate the necessity for genetic and molecular testing to aid in selecting appropriate monotherapeutic or combination treatment options to improve survival outcomes in patients with advanced or recurrent EC
- Devise a strategy to incorporate recently approved or emerging treatment options for patients with advanced or recurrent EC based on clinical trial findings
- Identify and monitor for, as well as manage and mitigate against, adverse reactions that can be caused by treatments that were recently approved for advanced or recurrent EC
Faculty Co-Chairs
Associate Professor of Medicine
Director, UFCOM Introduction to Clinical Medicine 1A & 1B
Program Director
Hematology/Oncology Fellowship
University of Florida
Gainesville, Florida
Martina C. Murphy, MD, does not have any real or apparent conflicts to disclose.
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas
Grants/Contracts: AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, Zentalis
Consulting Fees: Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, Zentalis
Case Development Faculty
Assistant Professor
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas
Michaela Onstad-Grinsfelder, MD, MPH, does not have any real or apparent conflicts to disclose.
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of June 30, 2022 through June 30, 2023, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Activity Details
Expires: June 30, 2023
Provided By
Integrity Continuing Education, Inc.
Statement of Commercial Support
This educational activity is supported by educational grants from Eisai Inc., GlaxoSmithKline, and Merck Sharp & Dohme Corp.
Target Audience
This educational activity has been designed to meet the needs of medical and gynecologic oncologists, physician assistants, and nurse practitioners who treat and manage patients with gynecologic malignancies, with a focus on the community-based clinician.
Activity Description
The treatment options for advanced or recurrent endometrial cancer (EC)
have changed dramatically in the last five years. Molecular testing to
identify patients that could benefit from targeted treatments is now
recommended for all patients. Choosing the optimal treatment can be complex
as treatment planning must consider molecular signatures, safety and efficacy
data, patient and tumor characteristics, and guideline recommendations.
In this edition of In the Clinic, Drs. Murphy and Westin will unpack
the latest clinical trial data and review best practices for approaching
treatment for these patients.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Elucidate the necessity for genetic and molecular testing to aid in selecting appropriate monotherapeutic or combination treatment options to improve survival outcomes in patients with advanced or recurrent EC
- Devise a strategy to incorporate recently approved or emerging treatment options for patients with advanced or recurrent EC based on clinical trial findings
- Identify and monitor for, as well as manage and mitigate against, adverse reactions that can be caused by treatments that were recently approved for advanced or recurrent EC
Faculty Co-Chairs
Associate Professor of Medicine
Director, UFCOM Introduction to Clinical Medicine 1A & 1B
Program Director
Hematology/Oncology Fellowship
University of Florida
Gainesville, Florida
Martina C. Murphy, MD, does not have any real or apparent conflicts to disclose.
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas
Grants/Contracts: AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, Zentalis
Consulting Fees: Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, Zentalis
Case Development Faculty
Assistant Professor
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas
Michaela Onstad-Grinsfelder, MD, MPH, does not have any real or apparent conflicts to disclose.
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of June 30, 2022 through June 30, 2023, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Optimizing Care of Veterans with Advanced Renal Cell Carcinoma: Incorporating Immunotherapies and Targeted Agents into Clinical Practice
StartActivity Details
1.0 Contact Hour(s)
Expires: June 15, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with renal cell carcinoma.
Learning Objectives
After completing this program, participants should be able to:
- Analyze recent clinical trial data regarding the efficacy and safety of first-line immunotherapy-containing regimens for advanced renal cell carcinoma (RCC).
- Identify and manage immune-related adverse events (irAEs) associated with immunotherapy-containing regimens.
- Assess the appropriate roles for new therapies in the current treatment landscape of relapsed or refractory advanced RCC in the veteran population.
- Integrate new therapeutic approaches into treatment plans for veterans with RCC within the VHA/MHS/DoD healthcare system.
Activity Description
This educational activity is designed to provide the healthcare team with the latest developments and critical insights into the management of advanced renal cell carcinoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application of available therapies.
Statement of Educational Need
The treatment paradigm for advanced RCC has evolved rapidly in recent years with the arrival of next-generation TKIs and combination approaches with immune checkpoint inhibitors. Despite these advancements, patients continue to exhibit inferior outcomes. To provide optimal patient care, clinicians require in-depth education surrounding these novel treatments, including the most recent clinical data regarding the efficacy and safety of these agents, current guideline recommendations, appropriate management of potential AEs, and approaches to select among available options and combinations in the first-line setting and beyond for patients with advanced RCC. Therefore, clinician education is urgently needed to improve outcomes for patients with RCC.
Faculty
Professor of Medicine and Urology
David Geffen School of Medicine at UCLA
Chief, Division of Hematology-Oncology, VA GLAHS
Los Angeles, CA
Disclosure
- Research Grant: Novartis, Johnson & Johnson, Merck, Astellas, Medivation
- Member, Speakers Bureau: J&J, Bayer
- Consultant: Amgen, Ambryx, Clovis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Eisai, Exelixis, and Merck Sharp & Dohme Corp.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: June 15, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with renal cell carcinoma.
Learning Objectives
After completing this program, participants should be able to:
- Analyze recent clinical trial data regarding the efficacy and safety of first-line immunotherapy-containing regimens for advanced renal cell carcinoma (RCC).
- Identify and manage immune-related adverse events (irAEs) associated with immunotherapy-containing regimens.
- Assess the appropriate roles for new therapies in the current treatment landscape of relapsed or refractory advanced RCC in the veteran population.
- Integrate new therapeutic approaches into treatment plans for veterans with RCC within the VHA/MHS/DoD healthcare system.
Activity Description
This educational activity is designed to provide the healthcare team with the latest developments and critical insights into the management of advanced renal cell carcinoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application of available therapies.
Statement of Educational Need
The treatment paradigm for advanced RCC has evolved rapidly in recent years with the arrival of next-generation TKIs and combination approaches with immune checkpoint inhibitors. Despite these advancements, patients continue to exhibit inferior outcomes. To provide optimal patient care, clinicians require in-depth education surrounding these novel treatments, including the most recent clinical data regarding the efficacy and safety of these agents, current guideline recommendations, appropriate management of potential AEs, and approaches to select among available options and combinations in the first-line setting and beyond for patients with advanced RCC. Therefore, clinician education is urgently needed to improve outcomes for patients with RCC.
Faculty
Professor of Medicine and Urology
David Geffen School of Medicine at UCLA
Chief, Division of Hematology-Oncology, VA GLAHS
Los Angeles, CA
Disclosure
- Research Grant: Novartis, Johnson & Johnson, Merck, Astellas, Medivation
- Member, Speakers Bureau: J&J, Bayer
- Consultant: Amgen, Ambryx, Clovis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Eisai, Exelixis, and Merck Sharp & Dohme Corp.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Seeing Nonmelanoma Skin Cancers Through a New Lens: The Role and Place of Immunotherapy: A Care Team Forum®
StartActivity Details
Expires: June 13, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for medical oncology and dermatology clinicians who manage patients with nonmelanoma skin cancer (NMSC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with difficult-to-treat nonmelanoma skin cancer (NMSC) based on current staging systems, risk factors, and guidelines
- Select appropriate immunotherapy for advanced NMSC based on available data and approved indications
Activity Description
Join our multidisciplinary experts for an interactive program offering privileged insights into the evolving nonmelanoma skin cancer (NMSC) treatment paradigm. Core topics include evidence-based strategies for identifying patients at increased risk for disease progression, pinpointing the evolution of advanced disease, and integrating immunotherapy as a key component of the armamentarium against advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). A patient panelist augments these insights by highlighting aspects of their own treatment journey.
Chair
Professor, Dermatology
Head of Dermato-oncology
Department of Dermatology
University of Kiel
Kiel, Germany
Faculty
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Mass General Cancer Center
Boston, United States
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
George Washington University School of Medicine & Health Sciences
Washington DC, United States
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Prof. Axel Hauschild, MD, has relevant financial relationships with Amgen, BMS, Merck/Pfizer, MSD/Merck, Novartis, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme (Grant/Research Support).
David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Consultant); Checkpoint Therapeutics (Equity); Kartos Therapeutics, NeoImmune Tech, Inc, Regeneron (Research).
Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Almirall, Castle Biosciences, Regeneron, Sanofi (Speaker/Speaker’s Bureau); Jounce Therapeutics, PHD Biosciences, (Consultant); Almirall (Advisor); Lazarus AI, Science 37, Inc. (Stock/Shareholder).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
Expires: June 13, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for medical oncology and dermatology clinicians who manage patients with nonmelanoma skin cancer (NMSC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with difficult-to-treat nonmelanoma skin cancer (NMSC) based on current staging systems, risk factors, and guidelines
- Select appropriate immunotherapy for advanced NMSC based on available data and approved indications
Activity Description
Join our multidisciplinary experts for an interactive program offering privileged insights into the evolving nonmelanoma skin cancer (NMSC) treatment paradigm. Core topics include evidence-based strategies for identifying patients at increased risk for disease progression, pinpointing the evolution of advanced disease, and integrating immunotherapy as a key component of the armamentarium against advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). A patient panelist augments these insights by highlighting aspects of their own treatment journey.
Chair
Professor, Dermatology
Head of Dermato-oncology
Department of Dermatology
University of Kiel
Kiel, Germany
Faculty
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Mass General Cancer Center
Boston, United States
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
George Washington University School of Medicine & Health Sciences
Washington DC, United States
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Prof. Axel Hauschild, MD, has relevant financial relationships with Amgen, BMS, Merck/Pfizer, MSD/Merck, Novartis, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme (Grant/Research Support).
David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Consultant); Checkpoint Therapeutics (Equity); Kartos Therapeutics, NeoImmune Tech, Inc, Regeneron (Research).
Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Almirall, Castle Biosciences, Regeneron, Sanofi (Speaker/Speaker’s Bureau); Jounce Therapeutics, PHD Biosciences, (Consultant); Almirall (Advisor); Lazarus AI, Science 37, Inc. (Stock/Shareholder).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.